Gastric Cancer Diagnostic Market By Product, By Disease Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The gastric cancer diagnostic market was valued at $2.3 billion in 2022 and is estimated to reach $3.8 million by 2032, exhibiting a CAGR of 5.3% from 2023 to 2032. Gastric cancer diagnostic refers to the process of identifying and confirming the presence of gastric (stomach) cancer in an individual. It involves various medical procedures and tests aimed at detecting and diagnosing this type of cancer. The goal of gastric cancer diagnostics is to determine if a person has malignant (cancerous) growth in the stomach, understand its characteristics, including the type and stage of the cancer, and provide valuable information to guide treatment decisions. Gastric cancer has become the second leading cause of cancer-related deaths worldwide, and its epidemiology has undergone significant changes in recent decades. During endoscopy or surgery, a tissue sample (biopsy) is collected from the suspicious area in the stomach. The biopsy is then examined by a pathologist to confirm the presence of cancer and determine its type and grade.

The gastric cancer diagnostic market has experienced significant growth owing to rise in prevalence of gastric cancer and advancements in diagnostics technology. For instance, according to the National Library of Medicine, a total of 1,089,103 new stomach cancer cases were reported globally for 2020. In addition, rise in awareness, screening programs about the importance of stomach cancer screening and the implementation of organized screening programs in some regions lead to early detection and diagnosis of gastric cancer, which fuels the market growth.

Furthermore, the rise in trend toward personalized or precision medicine fosters the use of molecular and genetic testing to identify specific genetic markers and tailor treatments to individual patients, boosting the demand for diagnostic tests and propelling the market growth. Furthermore, the ongoing advancements in diagnostic tools and technologies, such as improved endoscopy, molecular & genetic testing, and imaging techniques, enhance the accuracy and early detection of gastric cancer, which is expected to drive the market growth.

The gastric cancer diagnostic market is segmented into product, disease type, end user, and region. By product, the market is segregated into reagents & consumables and instruments. By disease type, the market is categorized into adenocarcinoma, gastric lymphoma, and others. By end user, the market is classified into hospitals, diagnostic laboratories, and diagnostic imaging centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

Major key players that operate in the gastric cancer diagnostic market are Bio-Rad Laboratories, Inc., Qiagen NV., Agilent Technologies, Inc., Exact Sciences Corporation, MiRXES Pte Ltd, Hipro Biotechnology Co.,Ltd., Fulgent Genetics, Endofotonics Pte Ltd, Abbott Laboratories, and F. Hoffmann-La Roche Ltd. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the gastric cancer diagnostic market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer diagnostic market analysis from 2022 to 2032 to identify the prevailing gastric cancer diagnostic market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the gastric cancer diagnostic market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global gastric cancer diagnostic market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product

Reagents and Consumables
Instruments

By Disease Type

Adenocarcinoma
Gastric Lymphoma
Others

By End User

Hospitals
Diagnostic Laboratories
Diagnostic Imaging Centers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Exact Sciences Corporation
Fulgent Genetics
Endofotonics Pte Ltd
MiRXES Pte Ltd
F. Hoffmann-La Roche Ltd.
Agilent Technologies, Inc.
Hipro Biotechnology Co.,Ltd.
Abbott Laboratories
Qiagen NV.
Bio-Rad Laboratories, Inc.

Product Code: A210376

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in incidence of gastric cancer
  - 3.4.1.2. Advancements in diagnostic technologies
  - 3.4.1.3. Growing awareness about gastric cancer
- 3.4.2. Restraints
  - 3.4.2.1. High diagnostic cost
- 3.4.3. Opportunities
  - 3.4.3.1. Significant unmet need in cancer diagnosis
  - 3.4.3.2. Growth opportunities in emerging markets

CHAPTER 4: GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Reagents and Consumables
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Instruments
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Adenocarcinoma
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Gastric Lymphoma
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Diagnostic Laboratories
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Diagnostic Imaging Centers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: GASTRIC CANCER DIAGNOSTIC MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Product
- 7.2.3. Market size and forecast, by Disease Type
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Product
  - 7.2.5.1.2. Market size and forecast, by Disease Type
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Product
  - 7.2.5.2.2. Market size and forecast, by Disease Type
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Product
  - 7.2.5.3.2. Market size and forecast, by Disease Type
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Product
- 7.3.3. Market size and forecast, by Disease Type
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Product
  - 7.3.5.1.2. Market size and forecast, by Disease Type
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Product
  - 7.3.5.2.2. Market size and forecast, by Disease Type
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Product
  - 7.3.5.3.2. Market size and forecast, by Disease Type
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Product
  - 7.3.5.4.2. Market size and forecast, by Disease Type
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Product
  - 7.3.5.5.2. Market size and forecast, by Disease Type
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Product
  - 7.3.5.6.2. Market size and forecast, by Disease Type
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Product
- 7.4.3. Market size and forecast, by Disease Type
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Product
  - 7.4.5.1.2. Market size and forecast, by Disease Type
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Product
  - 7.4.5.2.2. Market size and forecast, by Disease Type
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Product
  - 7.4.5.3.2. Market size and forecast, by Disease Type
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Product
  - 7.4.5.4.2. Market size and forecast, by Disease Type
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Product
  - 7.4.5.5.2. Market size and forecast, by Disease Type
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Product
  - 7.4.5.6.2. Market size and forecast, by Disease Type
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Product
- 7.5.3. Market size and forecast, by Disease Type
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Product
  - 7.5.5.1.2. Market size and forecast, by Disease Type
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Product
  - 7.5.5.2.2. Market size and forecast, by Disease Type
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Product
  - 7.5.5.3.2. Market size and forecast, by Disease Type
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Product
  - 7.5.5.4.2. Market size and forecast, by Disease Type
  - 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Bio-Rad Laboratories, Inc.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Qiagen NV.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Agilent Technologies, Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. MiRXES Pte Ltd
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Key strategic moves and developments
9.5. Hipro Biotechnology Co.,Ltd.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
9.6. Fulgent Genetics
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Exact Sciences Corporation
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Endofotonics Pte Ltd
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
9.9. Abbott Laboratories
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. F. Hoffmann-La Roche Ltd.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance